| Followers | 71 |
| Posts | 8989 |
| Boards Moderated | 0 |
| Alias Born | 03/06/2016 |
Saturday, October 28, 2023 4:56:52 PM
So easy to rebuttal....
First time leading a company...and yet, he single-handedly saved it from BK and is now debt-free with $150 Million in the bank That makes a great CFO....not CEO
First time doing trials...and yet, every trial has been a success...Success??? Then where is the TLD on all those successful trials???
First time trying to commercialize...and yet, we are 6-12 months away from commercializing A2-73 for Rett...How do you know that? We haven't seen the TLD yet???
First time dealing with regulators...and yet, he was smart enough to hire the top-dog from the FDA to ensure our approval process...You got to be kidding...How many years has it been since he hired his first ex-FDA'er? Everyone was touting back then that would expedite trials...LOL...nothing was expedited...Lets hope his 3RD ex-FDA-er works out.....
First time dealing directly with shareholders...as it turns out, the largest shareholders of AVXL are institutions....Yet the share price is controlled by the fudster bas with his daily hype (except when he is selling and reloading). If tutes were committed (besides Index funds) then we wouldn't be at $5. More likely $25....
Quite an accomplishment, no? Funny things happen when one is so heavy invested that they fail to see reality...
Lets hope the RETT results are unambiguous and we reach true value.
First time leading a company...and yet, he single-handedly saved it from BK and is now debt-free with $150 Million in the bank That makes a great CFO....not CEO
First time doing trials...and yet, every trial has been a success...Success??? Then where is the TLD on all those successful trials???
First time trying to commercialize...and yet, we are 6-12 months away from commercializing A2-73 for Rett...How do you know that? We haven't seen the TLD yet???
First time dealing with regulators...and yet, he was smart enough to hire the top-dog from the FDA to ensure our approval process...You got to be kidding...How many years has it been since he hired his first ex-FDA'er? Everyone was touting back then that would expedite trials...LOL...nothing was expedited...Lets hope his 3RD ex-FDA-er works out.....
First time dealing directly with shareholders...as it turns out, the largest shareholders of AVXL are institutions....Yet the share price is controlled by the fudster bas with his daily hype (except when he is selling and reloading). If tutes were committed (besides Index funds) then we wouldn't be at $5. More likely $25....
Quite an accomplishment, no? Funny things happen when one is so heavy invested that they fail to see reality...
Lets hope the RETT results are unambiguous and we reach true value.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
